MOTS-c in 2026: Phase 2a Trial Data, Exercise-Mimetic Research & WADA's Prohibited List

MOTS-c is now in a Phase 2a human trial (NCT07505745) for insulin sensitivity, backed by a decade of mouse exercise and aging data — and it's on WADA's Prohibited List. Here's what's actually established versus what's just forum talk.